Current anti-angiogenic strategies in cancer therapy, including VEGF neutralization antibodies and small inhibitors of VEGF receptors, are focusing on blocking the VEGF signaling by targeting VEGF protein and specific downstream signaling pathways, respectively. Here, VEGFA is linked to cancer.